Related Experiment Video
Updated: May 29, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Cardiovascular risk stratification and antihypertensive therapy according to guidelines in the outpatient setting
Jörg Slany1, Günther Nirnberger, Lothar A Pittrow
1Specialist for Internal Medicine, Cardiology & Angiology, Vienna, Austria.
Insights
Austrian physicians often underestimate cardiovascular risk in hypertension patients. Guidelines for combination therapy are not always followed, but candesartan effectively controls blood pressure.
Area of Science:
- Cardiology
- Hypertension Management
- Clinical Practice Guidelines
Background:
- The adoption of the European Society of Hypertension/European Society of Cardiology (ESH/ESC) 2007 hypertension guidelines and their 2009 reappraisal among Austrian practitioners is not well-documented.
- A non-interventional trial was conducted to assess the understanding and application of these guidelines in clinical practice.
Purpose of the Study:
- To evaluate the accuracy of cardiovascular risk categorization by office-based physicians compared to independent adjudication using ESH/ESC charts.
- To assess compliance with combination therapy recommendations for grade 2 and 3 hypertension.
- To evaluate the efficacy and tolerability of candesartan treatment.
Main Methods:
- A non-interventional trial involving 3,488 ambulatory hypertensive patients in Austria.
- Physicians' risk assessment was compared against an independent risk adjudication using the same data and ESH/ESC methodology.
- Compliance with combination therapy and the effectiveness of candesartan (alone or with hydrochlorothiazide) were assessed.
Main Results:
- Physicians incorrectly assessed cardiovascular risk in approximately 60% of patients, with a significant tendency towards underestimation.
- Despite guidelines recommending initial combination therapy for hypertension ≥160/90 mmHg, 15.4% of these patients received candesartan monotherapy.
- Candesartan, alone or with hydrochlorothiazide (HCTZ), achieved target blood pressure (≤140/90 mmHg) in 81.6% of patients with grade 1-3 hypertension.
Conclusions:
- There is a need for improved communication of hypertension guidelines regarding individual risk assessment and therapy algorithms in outpatient settings.
- Candesartan, as monotherapy or in combination with HCTZ, demonstrates effectiveness and good tolerability for blood pressure control in most hypertensive patients.
Unlabelled:
BASIC CONCEPTS AND METHODOLOGY: Acceptance of the ESH/ESC 2007 hypertension guidelines and their reappraisal 2009 are not known by Austrian practitioners. Therefore, within the frame of a noninterventional trial we investigated 3,488 ambulatory hypertensive patients. Primary goal was the evaluation of the assignment to cardiovascular risk categories according to the ESH/ESC charts by office-based physicians compared to an independent risk adjudication using the same data and method. Further goals were assessment of compliance with the recommendation to start combination treatment in grade 2 and 3 hypertension and efficacy and tolerability of treatment with candesartan.
Results:
The comparison revealed incorrect physicians' risk assessment for approximately 60% of the patients with a strong tendency for underestimation. Despite guidelines recommending an initial combination therapy for hypertension ≥160/90 mmHg, 15.4% of these patients still received candesartan as a monotherapy. Target blood pressure ≤140/90 mmHg could be well achieved (in 81.6%) with candesartan as monotherapy or combined with hydrochlorothiazide (HCTZ) for hypertension grade 1-3.
Conclusions:
Guidelines for assessment of individual risk and derived therapy algorithms should be better communicated in the outpatient setting. Candesartan alone or combined with HCTZ is an effective and well tolerated therapeutic option to control blood pressure in the majority of patients.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Atherosclerosis III: Management
Hypertension V: Nursing Management
Cardiomyopathy V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Hypertension III: Clinical Manifestations and Diagnostic Studies